Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients

Journal of Immunotherapy

Volumn 20, Issue 1, 1997, Pages 70-71

  MacLean, Grant D ^a   Reddish, Mark A ^b   Michael Longenecker, B ^c  

^a Cancer Institute   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Biomira Inc   (Canada)

Author keywords

1 CA27.29; Immunotherapy; MUC; Prognosis; Sialyl; Tn

Indexed keywords

CANCER VACCINE; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; COLON ADENOCARCINOMA; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECURRENCE RISK; TREATMENT OUTCOME;

ADENOCARCINOMA; BREAST NEOPLASMS; CA-15-3 ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; NUCLEIC ACID HYBRIDIZATION; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 0031466006     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199701000-00008     Document Type: Article

References (42)

1. Strous GJ, Dekker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol 1992:48:57-92.
2. Devine PL, McKenzie IFC. Mucins: structure, function, and associations with malignancy. BioEssays 1992;14:619-25.
3. Hanisch F-G, Uhlenbruck G, Peter-Katalinic J, Egge H, Dabrowski J, Dabrowski U. Structure of neutral and O-linked polylactosaminoglycans on human skim milk mucins. J Biol Chem 1989;264:872-83.
4. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe DW. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. PNAS 1988;85:2320-3.
5. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
6. Litenberg MJL, Vos HL, Gennisen AMC, Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternate amino termini. J Biol Chem 1990;265:5573-8.
7. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-32.
8. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47:5476-82.
9. Devine PL, Warren JA, Ward BG, McKenzie IFC, Layton GT. Glycosylation and exposure of tumor-associated epitopes on mucins. J Tumor Marker Oncol 1990;5:11-26.
10. Muss H, Beveridge R, Chan D, et al. TRUQUANT BR RIA for CA27.29 antigen is highly predictive of relapse in stage II and III breast cancer. Proc ASCO 1996;15:117.
11. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992;10:95-101.
12. Bresalier RS, Niv Y, Byrd JC, et al. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 1991;87:1037-45.
13. van de Wiel-van Kemenade E, Ligtenberg MJL, de Boer AJ, et al. Episialin (MUC1) inhibits cytotoxic PBL-target cell interaction. J Immunol 1993;151:767-76.
14. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:7159-63.
15. Hayes DF, Silberstein DS, Rodrique SW, Kufe DW. DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody coated targets. J Immunol 1990; 145: 962-70.
16. Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 1992;52:4741-6.
17. Fung PYS, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-Ha). Cancer Res 1991;51:1170-6.
18. MacLean GD, Longenecker BM. The immune system, cancer antigens and immunotherapy. Contemp Oncol 1992;1:4-10.
19. Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of THERATOPE sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996;42:303-9.
20. Ogata S, Uehara H, Chen A, Itzkowitz SH. Mucin gene expression in colonic tissues and cell lines. Cancer Res 1991; 52: 5971-8.
21. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
22. Lan MS, Hollingsworth MA, Metzgar RS. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res 1990;50:2997-3001.
23. Bresalier RS, Niv Y, Byrd JC, et al. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastatis. J Clin Invest 1991;87:1037-45.
24. Osako M, Yonezawa S, Siddiki B, et al. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 1993;71:2191-9.
25. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988;11-12:55-101.
26. Hanski C, Drechsler K, Hanisch F-G, et al. Altered glycosylation of the MUC-1 protein core contributes to the colon carcinoma-associated increase of mucin-bound sialyl-Lewis* expression. Cancer Res 1993;53:4082-8.
27. Ho JJL, Siddiki B, Kim YS. Association of sialyl-Lewis with MUC-1 apomucin in a pancreatic cancer cell line. Cancer Res 1995;55:3659-63.
28. Ho JJL, Kim YS. Serological pancreatic tumor markers and the MUC1 apomucin. Pancreas 1994;9:674-91.
29. Ho JJL, Cheng S, Kim YS. Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids. Biochem Biophys Res Commun 1995;210:866-73.
30. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker BM. Epitope mapping of MAb B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for by the human MUC-1 gene. J Tumor Marker Oncol 1992;7:19-27.
31. MacLean GD, Reddish MA, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconju gate plus Detox™ adjuvant. Cancer Immunol Immunother 1993;36:215-22.
32. + activation antigens on peripheral blood PBL populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 1995;61:470-4.
33. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated Sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 1996;19:59-68.
34. Frenette PS, Thirlwell MP, Trudeau M, Thomson DMP, Joseph L, Shuster JS. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Tumor Biol 1994;15:247-54.
35. Cox DR, Oakes D. Analysis of survival data. London: Chap-man & Hall, 1984.
36. Abacus Concepts. Berkeley, California: Survival tools for statview. Abacus Concepts, 1994.
37. Umpleby HC, Ranson DL, Williamson RCN. Peculiarities of mucinous colorectal carcinoma. Br J Surg 1985;71:715-8.
38. DeMascarel A, Coindre JM, deMascarel I, Trojani M, Maree D, Hoerni B. The prognostic significance of specific histologic features of carcinoma of the colon and rectum. Surg Gynecol Obstet 1981;153:511-4.
39. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992;10:95-101.
40. Reddish MA, Jackson L, Koganty RR, Qiu D, Hong W, Longenecker BM. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconjugate J 1996;13:1-12.
41. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995;26:432-9.
42. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmerman G, Hugh JC. The breast mucin MUC-1 as a novel adhesion ligand for endothelial ICAM-1 in breast cancer. Cancer Res 1996;56:4244-9.